Perrigo (NYSE: PRGO) reported Q2 EPS of $1.93, $0.05 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion.

GUIDANCE:

Perrigo now sees FY2016 EPS of $6.85-$7.15, versus the consensus of $8.19. The company notes revised expectations for the Rx segment on the adjustment

For earnings history and earnings-related data on Perrigo (PRGO) click here.